cardiogen shock adopt germani
pre-announce revenu week ago
new metric today formal report strong oper
margin driven lower-than-expect spend revenu
guidanc rais anoth vs pre-announce
guidanc rais januari revenu guid also
report japanes revenu put compani ahead
expect given broader market dynam surpris
see clean stori like outperform today expect
continu post beat feel share absolut valuat
ntm sale estim present less compel risk/reward particularli
compani grow bigger bigger base maintain neutral
patient procedur increas y/i driven substanti
y/i growth cardiogen shock y/i growth protect
pci surprisingli clinician momentum broader data
awar continu drive shock adopt
ebit margin exceed ebit margin came
estim thank spend forecast
stronger euro present slight risk gm think updat ebit
margin guidanc highli achiev increas effici
strength germani post y/i growth top
high-growth quarter year ago compani report
japanes revenu ahead estim alreadi japanes center
adopt impella guidanc center
manag temper expect reiter plan
method gradual roll-out
tax reform lift ep outlook anticip tax rate cut
point approxim vs
valuat rate neutral risk discuss
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
year confer provid preliminari revenu
updat model accordingli along earn
preview today compani re-affirmed sale figur provid
addit detail impella revenu ou
impella sale led y/i growth germani
japanes revenu impella patient util manag
note protect pci util increas emerg util
shock grew overal seem factor drive impella adopt
remain stabl posit name grow physician awar around
cardiogen shock continu penetr german market
gross margin better estim overal ebit margin
better model lower spend
gaap ep includ one-tim incom tax expens tax
reform excess benefit sbc
actualsbtig estimate varianceu impella sale trial impella sale revenu growth net incom ep ep bpssg spend bpsr spend bpsebit bpstax bpssourc btig estim compani adj ep exclud one-tim incom tax expens result tax report basi ep impact benefit due adopt stock-based comp account one-tim expens tax reform varianc
make minim chang revenu increas intern sale
slightli go forward new revenu estim
believ full year oper margin outlook may
conserv ebit margin estim increas
previous spur signific beat quarter ebit line
also adjust model anticip lower tax rate
rais ep forecast
rate neutral feel compani above-averag revenu
growth gross margin warrant premium multipl peer
share ntm revenu estim fewer near-term catalyst
move materi higher near-term think share risk-
reward roughli equal btig provid price target neutral-r
risk rate includ impella adopt investor expect potenti
reimburs chang even investor nois topic margin
pressur new invest strong weak trial enrol
outcom potenti competit multipl expans declin
impella sale impella sale net incom ep tax btig estim compani normal adj ep excess tax benefit relat stock-bas comp tax expens newold changentm medicalwmginot inc ingnnot factset data btig estimatespr ex-amortev/salescagrcompanytickerr ptpricemarket cap
abiom incom product fund total y/i good gross sg amort intangibles- total oper incom loss invest incom incom incom expens pre-tax incom incom gaap net incom gaap share non-gaap non-gaap non-gaap ex select calendar loss net product product product oper ep btig estim compani report
abiom revenu commercialnew impella unit asp stock impella cp cp unit cp asp cp stock impella unit asp stock impella rp rp unit rp asp rp stock stock y/i consol instal rate new growth impella y/i inventori inventori impella impella product trial impella impella product product y/i product btig estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
